BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC50 of 64 nM for MRCKbeta in SCC12 cells, Ki values of 0.0136 nM and 0.0233 nM for MRCKalpha/beta in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation.
Molekulargewicht:
348.44
Reinheit:
98.49
CAS Nummer:
[2226507-04-4]
Formel:
C20H24N6
Target-Kategorie:
Cdc42-binding kinase
Anwendungsbeschreibung:
MCE Product type: Reference compound1
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten